Einloggen

Thematische Bibliographien / IMMUNOPHARMACOLOGICAL

Inhaltsverzeichnis

Zeitschriftenartikel

Auswahl der wissenschaftlichen Literatur zum Thema „IMMUNOPHARMACOLOGICAL“

Autor: Grafiati

Veröffentlicht am 18. Mai 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "IMMUNOPHARMACOLOGICAL" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "IMMUNOPHARMACOLOGICAL"

1

Ielpo, M. T. L., A. Basile, R. Miranda, et al. "Immunopharmacological properties of flavonoids." Fitoterapia 71 (August 2000): S101—S109. http://dx.doi.org/10.1016/s0367-326x(00)00184-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Kovalenko, L. P., E. V. Shipaeva, S. V. Alekseeva, et al. "Immunopharmacological properties of noopept." Bulletin of Experimental Biology and Medicine 144, no. 1 (2007): 49–52. http://dx.doi.org/10.1007/s10517-007-0251-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Zhang, Jianmei, Stephanie Triseptya Hunto, Yoonyong Yang, Jongsung Lee, and Jae Youl Cho. "Tabebuia impetiginosa: A Comprehensive Review on Traditional Uses, Phytochemistry, and Immunopharmacological Properties." Molecules 25, no. 18 (2020): 4294. http://dx.doi.org/10.3390/molecules25184294.

Der volle Inhalt der Quelle

Annotation:

Tabebuia impetiginosa, a plant native to the Amazon rainforest and other parts of Latin America, is traditionally used for treating fever, malaria, bacterial and fungal infections, and skin diseases. Additionally, several categories of phytochemicals and extracts isolated from T. impetiginosa have been studied via various models and displayed pharmacological activities. This review aims to uncover and summarize the research concerning T. impetiginosa, particularly its traditional uses, phytochemistry, and immunopharmacological activity, as well as to provide guidance for future research. A comprehensive search of the published literature was conducted to locate original publications pertaining to T. impetiginosa up to June 2020. The main inquiry used the following keywords in various combinations in titles and abstracts: T. impetiginosa, Taheebo, traditional uses, phytochemistry, immunopharmacological, anti-inflammatory activity. Immunopharmacological activity described in this paper includes its anti-inflammatory, anti-allergic, anti-autoimmune, and anti-cancer properties. Particularly, T. impetiginosa has a strong effect on anti-inflammatory activity. This paper also describes the target pathway underlying how T. impetiginosa inhibits the inflammatory response. The need for further investigation to identify other pharmacological activities as well as the exact target proteins of T. impetiginosa was also highlighted. T. impetiginosa may provide a new strategy for prevention and treatment of many immunological disorders that foster extensive research to identify potential anti-inflammatory and immunomodulatory compounds and fractions as well as to explore the underlying mechanisms of this herb. Further scientific evidence is required for clinical trials on its immunopharmacological effects and safety.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Kawakita, Takuya. "Immunopharmacological effects of Kampo medicines." Folia Pharmacologica Japonica 132, no. 5 (2008): 276–79. http://dx.doi.org/10.1254/fpj.132.276.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Borriello, Francesco, Francescopaolo Granata, Gilda Varricchi, Arturo Genovese, Massimo Triggiani, and Gianni Marone. "Immunopharmacological modulation of mast cells." Current Opinion in Pharmacology 17 (August 2014): 45–57. http://dx.doi.org/10.1016/j.coph.2014.07.002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Simbirtsev, A. S. "Immunopharmacological aspects of the cytokine system." Bulletin of Siberian Medicine 18, no. 1 (2019): 84–95. http://dx.doi.org/10.20538/1682-0363-2019-1-84-95.

Der volle Inhalt der Quelle

Annotation:

Cytokines represent a unique family of endogenous polypeptide mediators of intercellular interaction. From an immunopharmacological point of view cytokines can be marked out as a new, separate immunoregulatory molecule system and have some common biochemical properties and pleiotropic type of biological activity. In the cytokine regulatory system both reduction and elevation of cytokine levels can cause pathology. Several endogenous systems exist to control cytokine elevation and prevent tissue pathology. When synthesized simultaneously, cytokines form a cytokine chain. Deletion of any unit of this chain leads to the break in the formation of immunopathology. Cytokines as therapeutic preparations have evident advantages but also some limitations such as pharmacokinetics with short circulation period, adverse effects due to pleiotropic mode of action, and injectable drug forms. Rational design for clinical cytokine application could be linked with the development of prolonged and local drug forms or personalized cytokine therapy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Farjam, Mojtaba, Guang-Xian Zhang, Bogoljub Ciric, and Abdolmohamad Rostami. "Emerging immunopharmacological targets in multiple sclerosis." Journal of the Neurological Sciences 358, no. 1-2 (2015): 22–30. http://dx.doi.org/10.1016/j.jns.2015.09.346.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Kouttab, N., M. Prada, and B. Brunetti. "Immunopharmacological profile of two synthetic tripeptides." International Journal of Immunopharmacology 10 (January 1988): 126. http://dx.doi.org/10.1016/0192-0561(88)90472-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

IVANOVSKA, NINA, STEFAN PHILIPOV, and PEPA GEORGIEVA. "IMMUNOPHARMACOLOGICAL ACTIVITY OF APORPHINOID ALKALOID OXOGLAUCINE." Pharmacological Research 35, no. 4 (1997): 267–72. http://dx.doi.org/10.1006/phrs.1996.9994.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Kirchhof, Julia, Liubov Petrakova, Alexandra Brinkhoff, et al. "Learned immunosuppressive placebo responses in renal transplant patients." Proceedings of the National Academy of Sciences 115, no. 16 (2018): 4223–27. http://dx.doi.org/10.1073/pnas.1720548115.

Der volle Inhalt der Quelle

Annotation:

Patients after organ transplantation or with chronic, inflammatory autoimmune diseases require lifelong treatment with immunosuppressive drugs, which have toxic adverse effects. Recent insight into the neurobiology of placebo responses shows that associative conditioning procedures can be employed as placebo-induced dose reduction strategies in an immunopharmacological regimen. However, it is unclear whether learned immune responses can be produced in patient populations already receiving an immunosuppressive regimen. Thus, 30 renal transplant patients underwent a taste-immune conditioning paradigm, in which immunosuppressive drugs (unconditioned stimulus) were paired with a gustatory stimulus [conditioned stimulus (CS)] during the learning phase. During evocation phase, after patients were reexposed to the CS, T cell proliferative capacity was significantly reduced in comparison with the baseline kinetics of T cell functions under routine drug intake (ƞp2 = 0.34). These data demonstrate, proof-of-concept, that learned immunosuppressive placebo responses can be used as a supportive, placebo-based, dose-reduction strategy to improve treatment efficacy in an ongoing immunopharmacological regimen.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!